In vitro study | In vitro, ZM-447439 selectively inhibited recombinant human Aurora A and B with IC50 of 110 and 130 nM, respectively, while inhibiting other different structural types of protein kinases, including the mitotic kinases CDK1 and PLK1, IC50>10 μm. The Aurora kinase inhibitor, ZM-447439, inhibited the growth of three types of cell lines, I .e., BON, QGP-1, and MIP-101, for 72 hours with an IC50 of 3 μm, 0.9 μm, and 3 μm, respectively, this effect was time-and dose-dependent. In addition, ZM-447439 effectively induced apoptosis by promoting DNA division and caspase 3 and 7 activation, and GEP-NET cells were arrested in G0/G1 and G2/M phases. In mouse embryos, ZM-447439 inhibition of Aurora kinase, by regulating the G2 to metaphase histone H3 serine 10 (H3S10Ph) with different perturbations at each embryo cycle, leads to abnormalities in the first two divisions. The latest research shows that ZM-447439 acts on cervical cancer SiHa cells, inhibits growth and apoptosis, and enhances the chemical sensitivity to Cisplatin. In vitro, ZM-447439 selectively inhibited recombinant human Aurora A and B with IC50 of 110 and 130 nM, respectively, while inhibiting other different structural types of protein kinases, including the mitotic kinases CDK1 and PLK1, IC50>10 μm. The Aurora kinase inhibitor, ZM-447439, inhibited the growth of three types of cell lines, I .e., BON, QGP-1, and MIP-101, for 72 hours with an IC50 of 3 μm, 0.9 μm, and 3 μm, respectively, this effect was time-and dose-dependent. In addition, ZM-447439 effectively induces apoptosis by promoting DNA division and caspase 3 and 7 activation, and causes GEP-NET cells to pause in G0/G1 and G2/M phases. In mouse embryos, ZM-447439 inhibition of Aurora kinase, by regulating the G2 to metaphase histone H3 serine 10 (H3S10Ph) with different perturbations at each embryo cycle, leads to abnormalities in the first two divisions. The latest research shows that ZM-447439 acts on cervical cancer SiHa cells, inhibits growth and apoptosis, and enhances the chemical sensitivity to Cisplatin. |